Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 2/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | WNT1 | P04628 | 11/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.40 |
| ▸ | GSK3B | P49841 | 9/20 | 0.40 |
| ▸ | CLK2 | P49760 | 2/20 | 0.39 |
| ▸ | CLK3 | P49761 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | IL2 | P60568 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13770530 | 0.87 | IRAK4 (0.41) | DYRK1ACLK2CLK3ALDH1A1CREBBP | |
| SCHEMBL14222423 | 0.86 | IL2 (0.39) | IKBKETBK1GSK3BALDH1A1IL2 | |
| SCHEMBL12848712 | 0.83 | GSK3B (0.41) | DYRK1AGSK3BALDH1A1LMNACREBBP | |
| SCHEMBL14172516 | 0.83 | MAPT (0.41) | DYRK1AALDH1A1IL2 | |
| SCHEMBL12848716 | 0.81 | ALDH1A1 (0.39) | WNT1DYRK1AGSK3BALDH1A1LMNA | |
| SCHEMBL12848463 | 0.81 | HDAC1 (0.38) | IKBKETBK1HDAC1IL2 | |
| SCHEMBL14172853 | 0.79 | NPC1 (0.40) | WNT1DYRK1AGSK3BALDH1A1LMNA | |
| SCHEMBL14223164 | 0.78 | PRMT5 (0.37) | WNT1DYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL12848873 | 0.77 | ABCB1 (0.46) | — | |
| SCHEMBL12848730 | 0.73 | MEN1 (0.42) | HDAC1HDAC2ALDH1A1CREBBPIL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779154-B2 | Fused ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2014-07-15 | — | — | US | disclosed |
| US-8779154-B2 | Fused ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2014-07-15 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009089305-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008039520-A2 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132513-A1 | FUSED RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NOD2, RORC, NLRP3 | IKBKE 151/4885TBK1 997/4885HDAC1 492/4885 |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | IKBKE 214/4885TBK1 729/4885HDAC1 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.